Cargando…
In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs
Coronavirus disease (COVID-19) is an emerging pandemic that threatens the world since the early days of 2020. Development of vaccines or new drugs against COVID-19 comprises several stages of investigation including efficacy, safety, and approval studies. A shortcut to this delicate pathway is compu...
Autores principales: | Elmorsy, Mohammad A., El-Baz, Ahmed M., Mohamed, Nashwa H., Almeer, Rafa, Abdel-Daim, Mohamed M., Yahya, Galal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475441/ https://www.ncbi.nlm.nih.gov/pubmed/34562220 http://dx.doi.org/10.1007/s11356-021-16427-4 |
Ejemplares similares
-
In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes
por: Shaldam, Moataz A., et al.
Publicado: (2021) -
In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease
por: Mostafa, Islam, et al.
Publicado: (2021) -
Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation
por: Voss, Linda, et al.
Publicado: (2021) -
Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021) -
Profiling the physiological pitfalls of anti‐hepatitis C direct‐acting agents in budding yeast
por: Yahya, Galal, et al.
Publicado: (2021)